Collaborations on Imaging – The Medimmune’s Innovative Way

Jerry Wu, PhD, Medimmune Developments in Healthcare Imaging – Connecting with Industry 18th October 2017 Contents

1 A brief overview of Medimmune

2 Scientific collaborations

3 Scientific Interest Group for Imaging

2 A brief overview of Medimmune

Global Biologics Research and Development Arm of ~2,200 Employees in the US and UK

Robust pipeline of 120+ Biologics in Research & Development with 40+ projects in Clinical Stage Development California Gaithersburg Cambridge

3 Medimmune – Biologics arm of AstraZeneca

Late-stage Discovery and Early Development Development

Innovative Medicines and Early Development Unit (Small Molecules) Global Internal and Collaboration and Medicines external combinations Development Market opportunities MedImmune (Biologics)

4 Current therapeutic areas

Respiratory, Inflammation and Cardiovascular and Infectious Disease Oncology Autoimmunity Metabolic Disease Neuroscience

Main Therapeutic Areas Opportunity-driven

Protein Biologics Small Molecules Immuno-therapies Devices Engineering

5 RESPIRATORY, INFLAMMATION AND AUTOIMMUNITY ONCOLOGY (RIA) Medimmune R&D pipeline INFECTIOUS DISEASE (ID), NEUROSIENCE AND CARDIOVASCULAR AND METABOLIC DISEASE (CVMD) GASTROINTESINAL DISEASE

PHASE 1 PHASE 2 PHASE 2 PIVOTAL/PHASE 3

Durvalumab + MEDI-573 MEDI-565 MEDI0562 MEDI4276 Durvalumab MEDI0680 Metastatic ≥2nd Line Advanced Solid Tumors Solid Tumors Solid Tumors Stage III NSCLC Solid Tumors Breast Cancer Bladder Cancer Durvalumab/AZD5069/ Durvalmab + MEDI0680 MEDI1873 Durvalumab + Durvalumab Durvalumab MED9447 AZD9150 Solid Tumors Solid Tumors Solid Tumors 2nd Line SCCHN Solid Tumors Sq.Cell Carcinoma of H&N 1st Line NSCLC Tremelimumab + Durvalumab + Durvalumab + Durvalumab + Durvalmab + MEDI9197 MEDI9447 MEDI0562 Tremelimumab Tremelimumab Tremelimumab Tremelimumab Solid Tumors Solid Tumors Solid Tumors Hepatocellular carcinoma Gastric Cancer 1st Line SCCHN 1st Line NSCLC Durvalumab + Durvalumab or Durvalumab + Durvalumab + Durvalumab + Durvalumab + IRESSA (MEDI9929) Monalizumab (Tremelimumab or AZD9150) Tremelimumab Tremelimumab Non-Small Cell Lung Cancer Asthma/Atopic Dermatitis Neuromyelitis Optica Solid Tumors Diffuse large B-cell lymphoma 1st Line Bladder Cancer 3rd Line NSCLC Durvalumab + Durvalumab + Durvalumab + Moxetumomab AZD9412 AZD1775 MEDI0562 selumetinib Pasudotox Asthma/COPD COPD Solid Tumors Solid Tumors Solid Tumors Hairy Cell Leukemia Durvalumab + Durvalumab+ MEDI9314 MEDI0382 MEDI6012 Benralizumab Tremelimumab Dabrafenb + Trametinib Atopic Dermatitis Diabetes/Obesity Acute Coronary Syndrome Severe Asthma Severe Asthma Solid Tumors Melanoma

MEDI8111 MEDI0700 MEDI4166 MEDI3902 Anifrolumab Systemic Erythematosus Prevention of Nosocomial Trauma/Bleeding Systemic Lupus Erythematosus Diabetes/Cardiovascular Systemic Lupus Erythematosus (Subcutaneous) Pseudomonas MEDI4893 MEDI7352 MEDI4920 MEDI1814 MEDI8897 Hospital-acquired Osteoarthritis Pain Primary Sjögren’s Syndrome Alzheimer’s Disease Passive RSV Prophylaxis Pneumonia / S. aureus * As of February 2017 MEDI7734 Anifrolumab MEDI8852 Myositis Lupus Nephritis Influenza A Treatment

MEDI5872 6 Primary Sjögren’s Syndrome Scientific Collaborations Academic collaboration highlights

INSTITUTION THERAPEUTIC AREA DESCRIPTION

• Joint PhD program supports joint thesis projects ALL • Novel Entrepreneur-in-Residence program • Research collaborations in neuro, biopharmaceutical research • Creation of CRUK-MEDI Alliance Laboratory ONCOLOGY • CRUK provides novel drug targets • We provides antibody libraries and antibody engineering technologies • First industry sponsor for Catalyst awards ALL • Call for proposals in MedImmune therapeutic areas • Goal is to collaborate on joint projects

• Collaborations in formulation science BPD • Multiple projects with joint steering committee

• Research and education collaborations across 4 campuses ALL • Jointly funded with UMB and Maryland Dept. of Business and Economic Development

AKK • Multiple projects with joint steering committee

In 2015, MedImmune published 550+ publications, in which there were 35+ high impact publications (impact factor > 15) 8 Scientific collaboration is a key driver behind our move

Laboratory of School of Clinical Molecular Biology Cambridge Institute Medicine

AZ/Medimmune R&D Centre and Corporate HQ building

Medimmune/AstraZeneca already have >100 collaborations with Cambridge

Site of planned Energy Centre Addenbrooke’s Hospital and R&D Enabling Building Future hospital site The Rosie Hospital

9 Key collaborations in Cambridge

...through collaborations ...through our Scientific ...with leading scientists in With the tech and biotech Excellence programme Cambridge organisations sector of events

10 LMB / AZ-Medi Blue Sky collaboration LMB Divisions

Cell Biology

Neurobiology

Protein and Nucleic Acid Chemistry

Structural Studies

Core Technology Facilities From mass spectrometry and nuclear magnetic resonance to scientific computing

11 Scientific Interest Group for Imaging Medimmune Cambridge 2020 Vision

Use our unique position and exceptional talent to build scientific innovation and collaboration to deliver impact for patients

13 Continuing progress on our 2020 Vision

• Collaboration opportunities – Developing externally facing platform to enable future collaboration and outreach with partners • Scientific focus – creation of Scientific Interest Groups (SIG) – Imaging – Machine Learning – Devices and Delivery – Genomics – Experimental Medicine

14 Scientific Interest Groups – What are they for?

• Allow the sharing of ideas & opportunities in distinct focus areas • Identify opportunities for collaboration within the local area • Share what is happening within functional & therapeutic areas • Discuss new technologies and platforms to apply these within the organisation • A forum to discuss how to solve scientific problems in relevant areas • Share information & ideas across the organisation – IMED/Medi/Spirogen/Definiens • Provide a link into the Medimmune 2025 Strategic focus areas

15 Imaging – part of Digital Health Initiative

• Digital pathology – Automated tissue and organ analysis – Predictive multiplexing IHC biomarkers – Improve pathology diagnosis through machine learning • Non invasive techniques – CT, PET and MRI – In vivo microscopy imaging for expressed biologics • Image analysis, machine learning and deep learning

16 Collaboration strategy for Scientific Interest Group

• Use networks to uncover partners with technology and capabilities in imaging – Brainstorm workshop and consult all therapeutic areas – Internally identify problems that require a solution – Based on nature of problem, reach out internal and external networks for solutions • Ultimate goal to access or acquire novel capabilities and technology

17 How will we work?

Reach out for collaborations Co-creation of solution with external experts and internal partners

Proof of Work with TAs/ concept & cross functional implement groups to identify Evaluate possible the key problems technology to solve for the problems

18 How we achieve our bold vision: Start Small, Think Big.

“Start small, think big. Don’t worry about too many things at once. Take a handful of simple things to begin with, and then progress to more complex ones. Think about not just tomorrow, but the future. Put a ding in the universe.” Steve Jobs

19 Our approach to challenges

1. Open Access 6. Maximal 2. Added Efficient Value SIG Imaging

5. 3. Scalable Flexible

4. Multi- modal

20 Acknowledgements

• Scientific Interest Group for Imaging • High Content Imaging at Medimmune Research • Informatics, Medimmune R&D • Medimmune Cambridge Site Leadership Team • AZ High Content Biology & AZ Quantitative Biology • … and everyone else who helps us do our jobs!

21 Thank you!

Jerry Wu, Chair of Scientific Interest Group for Imaging wuje@.com Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com

23